T-VIN

Collection and storage of tissue and blood samples from patients with vulval intraepithelial neoplasia receiving topical treatment, for future translational research.

Background

Cancer Research UK funded the 204 patient phase II RT3 VIN trial, investigating the topical application of either Imiquimod or Cidofovir for vulval intraepithelial neoplasia (VIN).

Building on RT3 VIN study

RT3 VIN assesses clinical endpoints but does not address what the precise biological mechanisms of the drug benefit are, whether these benefits are specific to HPV infected cells, and whether certain types of patients or infection are likely to benefit more from a particular treatment. Prospectively and properly collected blood and tissue samples will allow specialist translational investigations to address these questions.

High quality blood and tissue samples

T-VIN aims to collect a high quality set of blood and tissue samples for use by research groups with specific interests in translational research, immunology and cancer.

Priority on the use of samples will be:

• the mechanism of action of cidofovir
• length of treatment to response
• patient response (including immunological) to both the HPV infection and to treatment.

Blood and tissue samples will be routinely collected during the running of the trial and stored at the Wales Cancer Bank. Samples will be anonymous but will be able to be linked to the clinical data at the Centre for Trials Research

Related publications

• Tristram, A. et al. 2014. Activity, safety, and feasibility of cidofovir and imiquimod for treatment of vulval intraepithelial neoplasia (RT³VIN): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncology 15 (12), pp.1361-1368. (10.1016/S1470-2045(14)70456-5)